Information Provided By:
Fly News Breaks for June 14, 2018
MYL, INVA
Jun 14, 2018 | 08:28 EDT
After Mylan (MYL) announced the FDA has identified minor deficiencies that will delay the launch of its generic Advair product, Morgan Stanley analyst Matthew Harrison said he expects the market to view this as a positive for Innoviva (INVA), which he predicts will be up 5% or more on the news. Harrison, who continues to anticipate a generic Advair entry in 2018, keeps an Underweight rating on Innoviva shares.
News For INVA;MYL From the Last 2 Days
There are no results for your query INVA;MYL